We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

133 hedge funds and large institutions have $1.34B invested in Apellis Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 50 increasing their positions, 37 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $973M → $1.34B (+$371M)

38% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 24

35% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 37

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

19% more call options, than puts

Call options by funds: $43.1M | Put options by funds: $36M

5.29% more ownership

Funds ownership: 63.4% → 68.69% (+5.3%)

3% more funds holding

Funds holding: 129 → 133 (+4)

Holders
133
Holders Change
+4
Holders Change %
+3.1%
% of All Funds
2.62%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
33
Increased
50
Reduced
37
Closed
24
Calls
$43.1M
Puts
$36M
Net Calls
+$7.01M
Net Calls Change
-$1.55M

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$30.8M
2
State Street
State Street
Massachusetts
+$20.7M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$19M
4
Citadel Advisors
Citadel Advisors
Florida
+$15.4M
5
FCM
Farallon Capital Management
California
+$13.8M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$58.9M
2
O
OrbiMed
New York
-$15M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$15M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$11.1M
5
Morgan Stanley
Morgan Stanley
New York
-$8.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
FC
126
FORA Capital
Florida
$66K +$59.7K +2,156 New
SFS
127
Sowell Financial Services
Arkansas
$57K +$51.3K +1,854 New
AAMU
128
Amundi Asset Management US
Massachusetts
$46K – – –
Federated Hermes
129
Federated Hermes
Pennsylvania
$44K -$4.52M -163,197 -99%
Daiwa Securities Group
130
Daiwa Securities Group
Japan
$11K -$1.02K -37 -9%
TRCT
131
Tower Research Capital (TRC)
New York
$8K -$136K -4,905 -95%
AG
132
Advisor Group
Arizona
$3K – – –
IC
133
Ikarian Capital
Texas
$2K +$1.47K +53 New
O
134
OrbiMed
New York
– -$15M -623,859 Closed
HCM
135
Highbridge Capital Management
New York
– -$1.44M -59,664 Closed
Lazard Asset Management
136
Lazard Asset Management
New York
– -$1.27M -52,655 Closed
WA
137
Whitebox Advisors
Minnesota
– -$1.27M -52,645 Closed
SIM
138
Spark Investment Management
New York
– -$1.15M -47,900 Closed
PP
139
Paloma Partners
Connecticut
– -$1.13M -46,974 Closed
ECM
140
Element Capital Management
New York
– -$995K -41,291 Closed
Assenagon Asset Management
141
Assenagon Asset Management
Luxembourg
– -$586K -24,312 Closed
MAM
142
Myriad Asset Management
Hong Kong
– -$422K -17,548 Closed
TCM
143
Tenor Capital Management
New York
– -$423K -17,548 Closed
Nomura Holdings
144
Nomura Holdings
Japan
– -$355K -16,000 Closed
HI
145
HBK Investments
Texas
– -$338K -14,038 Closed
SAM
146
Symphony Asset Management
California
– -$338K -14,038 Closed
JG
147
Jefferies Group
New York
– -$324K -13,429 Closed
LI
148
Leap Investments
Illinois
– -$306K -12,700 Closed
AC
149
Aristeia Capital
Connecticut
– -$279K -11,600 Closed
ARTA
150
A.R.T. Advisors
New York
– -$224K -9,282 Closed
3 4 5
6
7

APLS Hedge Fund Activity: Q4 2019 in Review

133 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2019, worth a combined $1.34B — up 38% from $973M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new APLS positions and 24 closed out — a net gain of 9 holders — while 50 added to existing stakes and 37 trimmed.

The largest buyer was Barclays, adding an estimated $30.8M. The largest seller was Millennium Management, cutting an estimated $58.9M.

  • 133 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2019, up from 129 in Q3 2019.
  • Funds reported $1.34B of Apellis Pharmaceuticals stock for Q4 2019, up 38% quarter-over-quarter.
  • 33 funds opened new Apellis Pharmaceuticals positions in Q4 2019 and 24 closed out, a net change of +9 holders.
  • The largest Apellis Pharmaceuticals buyer in Q4 2019 was Barclays, an estimated $30.8M added.
  • The largest Apellis Pharmaceuticals seller in Q4 2019 was Millennium Management, an estimated $58.9M sold.

Based on aggregated 13F filings for Q4 2019.